The point about the seer data is that it is very consistent over time and it is vast. The idea from that is that it does not appear that we should be expecting any wild fluctuation in OAS from radically improved standard of care in the last few years. (the end)
i.e., things do not appear that they will be changing dramatically while our trial is running.
We have some further specifics like later stage III and IV I believe. Therefore we will surely not hit those stats which are broader and include I and II. ( just for starters )
When I put @Fosco or @Spreadsheets I assume a lot about how much effort and how far along in the details of a conversation to be...
The better outstanding question is to @Cotton at the moment
News 
Market Data 
Discover 
